
Cardiff Oncology faces potential $500M+ valuation hit as pivotal cancer trial data looms
Cardiff Oncology's Q1 2026 pivotal trial data for RAS-mutated colorectal cancer treatment carries catastrophic downside risk, with failure to meet FDA endpoints threatening the company's core development program. CEO Mark Erlander's oncology pipeline faces medium-probability regulatory rejection that could wipe out investor confidence in the biotech's market approval pathway.
















